- Home
- CCG vs INKT Comparison
CCG vs INKT Comparison
Compare CCG & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCG | INKT |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | 548 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.5M | 57.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCG | INKT |
|---|---|---|
| Price | $0.79 | $9.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $350.00 | $35.00 |
| AVG Volume (30 Days) | 60.6K | ★ 146.1K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $6.66 |
| 52 Week High | $1.54 | $76.00 |
Technical Indicators
Market Signals| Indicator | CCG | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 41.10 |
| Support Level | $0.74 | $6.80 |
| Resistance Level | $0.82 | $12.64 |
| Average True Range (ATR) | 0.02 | 0.67 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 74.83 | 8.32 |
Price Performance
Historical ComparisonAbout CCG Cheche Group Inc.
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.